We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+62.1%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$4.18B
AUM Growth
+$1.19B
Cap. Flow
+$143M
Cap. Flow %
3.41%
Top 10 Hldgs %
48.69%
Holding
88
New
15
Increased
28
Reduced
14
Closed
24
Avg Time Held
1.3 years
Top 10 Avg Time Held
1 year
Top 20 Avg Time Held
1 year

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$127M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$72.2M
3
BSX icon
Boston Scientific
BSX
+$68.3M
4
APRE icon
Aprea Therapeutics
APRE
+$62.5M
5
UNH icon
UnitedHealth
UNH
+$52.9M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$155M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$114M
3
BOLD icon
Audentes Therapeutics, Inc
BOLD
+$87.2M
4
CELG
Celgene Corp
CELG
+$55.9M
5
WMGI
Wright Medical Group Inc
WMGI
+$49.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.67%
2 Industrials 0.33%
3 Technology 0%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XNCR icon
76
Xencor
XNCR
$1.78B
– –
-879,627
Closed -$29.7M –
CMRX icon
77
DELISTED
Chimerix, Inc.
CMRX
– –
-3,235,795
Closed -$7.6M –
SDC
78
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
– –
-490,340
Closed -$6.81M –
LHCG
79
DELISTED
LHC Group LLC
LHCG
– –
-2,166
Closed -$246K –
CLVS
80
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-3,607,800
Closed -$14.2M –
LOGC
81
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
– –
-749,026
Closed -$8.1M –
FLXN icon
82
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-21,630
Closed -$296K –
ALXN
83
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-1,162,200
Closed -$114M –
MYOK
84
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-7,182
Closed -$375K –
WMGI
85
DELISTED
Wright Medical Group Inc
WMGI
– –
-2,404,157
Closed -$49.6M –
ALDR
86
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-8,244,896
Closed -$155M –
HZNP
87
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-14,700
Closed -$400K –
CELG
88
DELISTED
Celgene Corp
CELG
– –
-562,700
Closed -$55.9M –
1 2 3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2019 Portfolio in Review

As of Q4 2019, Redmile Group held 88 positions worth $4.18B, up 40% from $2.99B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group deployed $143M of net new capital in Q4 2019, opening 15 new positions and adding to 28 existing holdings. Its largest new stake was Biogen: 457,500 shares worth $136M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Audentes Therapeutics, Inc, an estimated $87.2M trimmed.

  • Redmile Group's largest Q4 2019 buy was Biogen: 457,500 shares worth $136M.
  • Redmile Group added most to Principia Biopharma Inc. Common Stock in Q4 2019, an estimated $72.2M increase.
  • Redmile Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $87.2M.
  • Redmile Group fully exited Alder Biopharmaceuticals in Q4 2019, selling an estimated $155M.
  • Redmile Group's ten largest holdings make up 49% of its $4.18B portfolio in Q4 2019.
  • Redmile Group opened 15 new positions and closed 24 in Q4 2019.
  • Redmile Group's portfolio value rose 40% quarter-over-quarter to $4.18B.

Based on Redmile Group's 13F filing for Q4 2019, filed 14 Feb 2020.